<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377052</url>
  </required_header>
  <id_info>
    <org_study_id>I172</org_study_id>
    <secondary_id>CAN-NCIC-IND172</secondary_id>
    <secondary_id>ORTHO-CAN-NCIC-IND172</secondary_id>
    <secondary_id>CDR0000493021</secondary_id>
    <secondary_id>B9E-CA-0485</secondary_id>
    <nct_id>NCT00377052</nct_id>
  </id_info>
  <brief_title>Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of Bortezomib and Gemcitabine in Patients With Relapsed Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy,&#xD;
      such as gemcitabine, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or by stopping them from dividing. Bortezomib may help gemcitabine work&#xD;
      better by making cancer cells more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib together with gemcitabine&#xD;
      works in treating patients with relapsed mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy (response rate) of bortezomib and gemcitabine hydrochloride in&#xD;
           patients with relapsed mantle cell lymphoma.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the time to progression and duration of response in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV on days 1, 4, 8, and 11 and gemcitabine hydrochloride IV over&#xD;
      30 minutes on days 1 and 8. Treatment repeats every 21 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3 months&#xD;
      thereafter until relapse/progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2006</start_date>
  <completion_date type="Actual">June 21, 2011</completion_date>
  <primary_completion_date type="Actual">April 21, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response (overall response rate with 95% confidence interval)</measure>
    <time_frame>each cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression at median time</measure>
    <time_frame>each cycle and every 3 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (median and range)</measure>
    <time_frame>each cycle and every 3 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of stable disease and progressive disease</measure>
    <time_frame>each cycle and every 3 months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bortezomib + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks</description>
    <arm_group_label>Bortezomib + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks</description>
    <arm_group_label>Bortezomib + Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed mantle cell lymphoma&#xD;
&#xD;
               -  Relapsed disease&#xD;
&#xD;
          -  Not refractory to prior therapy&#xD;
&#xD;
               -  Must have received 1-3 prior systemic chemotherapy regimens AND has had no&#xD;
                  disease progression while receiving chemotherapy or within 1 month of last dose&#xD;
                  of most recent therapy&#xD;
&#xD;
          -  Clinically and/or radiologically documented disease&#xD;
&#xD;
               -  At least 1 site of disease must be bidimensionally measurable by CT scan or MRI&#xD;
                  with ≥ 1 lesion meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Lymph nodes ≥ 1.5 cm x 1.5 cm by spiral CT scan&#xD;
&#xD;
                    -  Non-nodal lesion ≥ 1 cm x 1 cm by MRI, CT scan, or physical exam&#xD;
&#xD;
               -  No nonmeasurable disease only&#xD;
&#xD;
          -  No preexisting ascites or pleural effusion ≥ grade 2&#xD;
&#xD;
          -  No known CNS involvement by lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  LVEF ≥ 45% by echocardiogram or MUGA&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds containing boron or mannitol&#xD;
&#xD;
          -  No preexisting edema ≥ grade 2&#xD;
&#xD;
          -  No preexisting neuropathy (sensory and/or pain) ≥ grade 2&#xD;
&#xD;
          -  No preexisting shortness of breath ≥ grade 2&#xD;
&#xD;
          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer,&#xD;
             curatively treated in situ cancer of the cervix, or other solid tumors curatively&#xD;
             treated with no evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude compliance with&#xD;
             study requirements, including any of the following:&#xD;
&#xD;
               -  Serious uncontrolled infection&#xD;
&#xD;
               -  Uncontrolled or severe cardiovascular disease, including any of the following:&#xD;
&#xD;
                    -  Myocardial infarction within the past 6 months&#xD;
&#xD;
                    -  New York Heart Association class III-IV heart failure&#xD;
&#xD;
                    -  Uncontrolled angina&#xD;
&#xD;
                    -  Clinically significant pericardial disease&#xD;
&#xD;
                    -  Cardiac amyloidosis&#xD;
&#xD;
               -  Significant neurological disorder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior radioactive monoclonal antibody therapy&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  No prior investigational therapy (except for flavopiridol)&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of functioning bone marrow&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
               -  Low-dose, nonmyelosuppressive radiotherapy may be allowed&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Tom Kouroukis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Margaret and Charles Juravinski Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII, CCR, Hematology Research</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Kouroukis CT, Fernandez LA, Crump M, Gascoyne RD, Chua NS, Buckstein R, Turner R, Assouline S, Klasa RJ, Walsh W, Powers J, Eisenhauer E. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011 Mar;52(3):394-9. doi: 10.3109/10428194.2010.546015. Erratum in: Leuk Lymphoma. 2011 Jun;52(6):1160. Gascoyne, Randy D [added].</citation>
    <PMID>21323520</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

